

Recommendations from the Newborn Screening Advisory Panel: Working Towards a Future Pan-Canadian Coordinated Approach for Newborn Screening

Author name(s): Colleen Donder

Author institutional affiliations: Canada's Drug Agency

As a part of the Government of Canada's National Strategy for Drugs for Rare Disease, Canada's Drug Agency convened a Newborn Screening Advisory Panel to develop pan-Canadian guidance for newborn screening. The overall goal of the guidance is to help foster consistency in the conditions screened for in newborns across Canada; a report with recommendations was made publicly available on March 31, 2025.

This poster will provide an overview of the process for the development of the pan-Canadian newborn screening recommendations. It will describe the key nonbinding short-term (1 to 2 years) and medium-term to long-term (3 years or more) recommendations made by the advisory panel.

The recommendations relate to:

1. adopting a set of guiding principles to guide newborn screening work in Canada,
2. working towards a future pan-Canadian newborn screening governance model,
3. a recommended pan-Canadian list of conditions to screen for in newborns,
4. enhancing processes for adding or reassessing conditions on the recommended list,
5. criteria for adding or reassessing conditions on the recommended list, and
6. anticipating emerging conditions that could be added to the list in the future.

Through a concise and visual format, this poster aims to inform conference attendees about these recommendations and how they can support the advancement of the coordination of newborn screening in Canada.